We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Nanoparticles Loaded with Nitric Oxide Overcome Antibiotic-Resistant Skin Bacteria

By HospiMedica International staff writers
Posted on 14 May 2009
A team of drug developers has successfully treated superficial wounds infected with antibiotic-resistant bacteria by using nanoparticles containing nitric oxide.

Nitric oxide (NO) is produced by many cells throughout the body and has several important biologic functions including killing bacteria, healing wounds, and increasing blood flow by dilating blood vessels. More...
Utilizing NO as a therapeutic agent is difficult, however. "The problem is that nitric oxide is very short-lived, and until now, methods to deliver it to targeted tissues in the proper dosages have proven elusive," explained senior author Dr. Joel Friedman, professor of physiology, biophysics, and medicine at Albert Einstein College of Medicine (New York, NY, USA).

To get around this problem, investigators developed a novel type of nanoparticle that could store NO while dry and then slowly release it when exposed to moisture. To test these particles in an animal model, a population of mice suffering from skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) was used. For the study, the MRSA-mice were divided into three groups. One group was treated with the nanoparticles loaded with NO. A second group received nanoparticles lacking nitric oxide, while the third group received no treatment.

Results published in the April 23, 2009, online edition of the Journal of Investigative Dermatology revealed that a week after treatment wounds in the group treated with the NO-containing nanoparticles were significantly improved and smaller than lesions in the two other groups. Bacterial counts were significantly lower in the NO-treated group compared with the other groups, and the NO-treated group showed evidence of accelerated wound healing both visually and microscopically. There were no signs that the nanoparticles were in any way toxic to the animals.

These results encouraged the researchers to conclude that, "NO-releasing nanoparticles have the potential to serve as a novel class of topically applied antimicrobials for the treatment of cutaneous infections and wounds."

Related Links:
Albert Einstein College of Medicine




Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.